Mineralys Therapeutics logo

Mineralys TherapeuticsNASDAQ: MLYS

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

10 February 2023

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$571.34 M
-28%vs. 3y high
68%vs. sector
-vs. 3y high
-vs. sector
-27%vs. 3y high
64%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 21:02:43 GMT
$11.48-$0.69(-5.67%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

MLYS Latest News

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
globenewswire.com11 November 2024 Sentiment: POSITIVE

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.

The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
accesswire.com20 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com19 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com13 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud
accesswire.com12 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud
accesswire.com08 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud
accesswire.com06 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com05 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com03 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Mineralys Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
accesswire.com29 September 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is Mineralys Therapeutics?

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

What sector is Mineralys Therapeutics in?

Mineralys Therapeutics is in the Healthcare sector

What industry is Mineralys Therapeutics in?

Mineralys Therapeutics is in the Biotechnology industry

What country is Mineralys Therapeutics from?

Mineralys Therapeutics is headquartered in United States

When did Mineralys Therapeutics go public?

Mineralys Therapeutics initial public offering (IPO) was on 10 February 2023

What is Mineralys Therapeutics website?

https://mineralystx.com

Is Mineralys Therapeutics in the S&P 500?

No, Mineralys Therapeutics is not included in the S&P 500 index

Is Mineralys Therapeutics in the NASDAQ 100?

No, Mineralys Therapeutics is not included in the NASDAQ 100 index

Is Mineralys Therapeutics in the Dow Jones?

No, Mineralys Therapeutics is not included in the Dow Jones index

When was Mineralys Therapeutics the previous earnings report?

No data

When does Mineralys Therapeutics earnings report?

The next expected earnings date for Mineralys Therapeutics is 21 March 2025